Pathogenesis, Virological Characteristics, and Laboratory Detection Strategies for Nipah Virus (NiV)
Pathogenesis, Virological Characteristics, and Laboratory Detection Strategies for Nipah Virus (NiV)
Nipah virus (NiV) is an emerging zoonotic pathogen characterized by high pathogenicity and the capacity to cause sporadic cases and localized outbreaks in South and Southeast Asia. NiV can spill over from its natural reservoir, fruit bats, to humans through bat-contaminated food or intermediate hosts, and can also be transmitted through human-to-human contact under specific circumstances. Clinical manifestations present a broad spectrum, ranging from asymptomatic infection to acute respiratory disease and fatal encephalitis. Due to the high case fatality rate and nonspecific early symptoms, laboratory testing plays a crucial role in case confirmation, nosocomial infection prevention and control, and outbreak response. Overall, nucleic acid testing is more suitable for the etiological diagnosis of the acute phase; protein-based testing (antigen and antibody detection) is more applicable for supplementary confirmation, disease staging, and retrospective investigation. In result interpretation, the subject of detection, disease time window, sample type, and quality control conditions should be integrally considered, avoiding absolute conclusions based on a single test result.
Keywords: Nipah virus; Nucleic acid detection; Antigen detection; Antibody detection; RT-PCR; ELISA; Biosafety
I. Overview of Nipah Virus
Nipah virus belongs to the genus Henipavirus within the family Paramyxoviridae. Since its identification during the 1998–1999 outbreak in Malaysia and Singapore, NiV has been increasingly recognized as an important emerging infectious disease pathogen requiring continuous surveillance and preparedness. Its natural hosts are primarily fruit bats (Pteropodidae). It can be transmitted to humans through bat-contaminated food (e.g., insufficiently protected and processed fresh plant-based beverages), environmental exposure, or intermediate hosts (e.g., pigs); human-to-human transmission has also been observed in some outbreaks. Clinical manifestations of human infection are diverse, including fever, headache, respiratory symptoms, and neurological involvement. Severe cases can progress to serious encephalitis and respiratory failure, with high case fatality rates reported across different outbreaks.
II. Pathogenesis and Virological Characteristics of Nipah Virus
2.1 Pathogenesis
Research suggests that the pathogenicity of NiV is closely related to its cellular tropism, vascular damage, and multi-organ involvement, manifesting as a pathological process involving concurrent damage to the vascular, nervous, and respiratory systems.
(1) Major Cellular Tropisms
① Endothelial Tropism: The virus preferentially infects vascular endothelial cells, which can trigger widespread vasculitis and endothelial damage. Decreased endothelial barrier function leads to increased vascular permeability, forming a critical basis for tissue edema, hemorrhagic tendencies, and microcirculatory disturbances.
② Neural Tropism: The virus can invade and infect cells of the central nervous system, inducing parenchymal inflammation and functional impairment. This is a key mechanism underlying the risk of severe encephalitis and neurological sequelae.
③ Respiratory Tropism: The virus exhibits affinity for respiratory epithelial cells, which can cause respiratory symptoms. Under certain conditions, this is related to the risk of human-to-human transmission, necessitating enhanced prevention and control measures, especially in scenarios involving close-contact care and exposure to respiratory secretions.
(2) Pathology and Clinical Manifestations
① Systemic Vasculitis and Edema: Infection of endothelial cells and the resulting vasculitis can cause vascular damage in multiple organs. Clinically, this may manifest as pulmonary interstitial changes and pulmonary edema, and may also involve organs such as the kidneys.
② Neurological Damage: Both viral replication and immune-mediated inflammatory responses contribute to brain tissue injury, evident as manifestations related to diffuse encephalitis. Both the degree of vasculitis and the viral replication load may be associated with poor prognosis.
③ Multinucleated Giant Cell Formation: Infected cells can fuse to form syncytia-like structures, participating in the disruption of local tissue architecture and dysfunction.
2.2 Virological Characteristics
(1) Morphological and Physicochemical Properties
NiV is an enveloped, pleomorphic viral particle. Its envelope surface contains two key glycoproteins: the attachment (G) protein, responsible for receptor binding, and the fusion (F) protein, responsible for mediating membrane fusion. As an enveloped virus, NiV is generally sensitive to various detergents and common disinfectants. Regarding processing conditions such as heat inactivation, the dependency on sample matrix and process parameters must be emphasized: any inactivation protocol intended for use in risk mitigation (downgrading operations) should be validated and must be implemented in conjunction with the institution's biosafety system and risk assessment requirements, avoiding the substitution of empirical conditions for validation-based conclusions.
(2) Molecular Biological Characteristics
The NiV genome is a single-stranded, negative-sense RNA, approximately 18.2 kb in full length. It encodes major structural and functional proteins, including the nucleocapsid (N) protein, phosphoprotein (P), matrix (M) protein, fusion (F) protein, attachment (G) glycoprotein, and the large RNA-dependent RNA polymerase (L) protein. The N protein is present in high abundance within viral particles and is relatively conserved within the genus, thus holding significant application value in the selection of molecular detection targets and the design of antigens for immunological detection assays.
III. Nucleic Acid Detection of Nipah Virus
3.1 Basic Principles of Nucleic Acid Detection
(1) Detection Target: Targets viral RNA, converting low-abundance nucleic acid signals into detectable signals through nucleic acid amplification.
(2) Common Technical Approaches: Real-time reverse transcription polymerase chain reaction (RT-PCR) is predominant in clinical and public health laboratories. Isothermal amplification and other rapid molecular methods can be evaluated as supplements in specific scenarios, but systematic methodological validation (including analytical sensitivity, analytical specificity, precision, cross-reactivity, interference effects, etc.) should be completed and incorporated into the quality management system prior to application.
(3) Result Output Format: Typically presented as "detected" or "not detected," or may provide relative signal strength for auxiliary judgment. Signal strength should not be directly equated with infectiousness and requires comprehensive interpretation considering the disease stage, sample type, and sampling quality.
3.2 Applicable Sample Types and Application Scenarios
(1) Sample Types: Respiratory specimens and blood-based samples can be selected based on clinical presentation and testing strategy. When neurological symptoms are prominent, professionals can assess the value and feasibility of testing specific body fluid samples (e.g., cerebrospinal fluid). Sample selection should balance disease stage, sampling accessibility, expected viral distribution, and biosafety requirements.
(2) Applicable Scenarios:
① Early screening and confirmation of suspected acute infection;
② Case confirmation and assistance in close contact tracing during outbreak response;
③ Support for disease course monitoring and infection control assessment in severe cases.
(3) Key Prerequisites: Sample collection, transportation, preservation, and laboratory process control must comply with standard requirements. Procedures for pre-processing, nucleic acid extraction, amplification systems, and interpretation thresholds should maintain consistency and traceability to reduce the risk of false negatives and false positives caused by laboratory contamination.
3.3 Advantages and Limitations of Nucleic Acid Detection
(1) Advantages:
① High sensitivity for acute-phase infection;
② Facilitates early detection and rapid response;
③ Enables linkage with epidemiological investigations to build an evidence chain.
(2) Limitations:
① Highly dependent on sampling timing and sample quality;
② Differences in viral load across different anatomical sites may lead to inconsistent results;
③ Detection of nucleic acid indicates the presence of viral genetic material and does not automatically equate to the presence of transmissible live virus. Transmission risk assessment requires comprehensive judgment combining clinical stage, exposure context, and additional information.
3.4 Aladdin Related Products
Product Code | Product Name | Grade and Purity | Suitability for Nipah Virus Nucleic Acid Detection |
P743507 | UltraBio™ 2×Taq Master Mix (Dye Plus) | BioReagent, DNase, RNase free, Suitable for molecular biology, PCR Reagent, for DNA and RNA applications, 2× | Contains built-in dye, suitable for qualitative endpoint PCR workflows related to Nipah virus cDNA; nuclease-free formulation helps protect nucleic acid templates, facilitating gel loading and interpretation. |
U1507984 | UltraBio™ 2×Taq Master Mix (Without Dye) | -- | Dye-free design allows flexible pairing with fluorescent probes or subsequent electrophoresis detection; suitable for customized nucleic acid amplification workflows for Nipah virus. |
P751573 | UltraBio™ Anstart Taq-D qPCR Master Mix (2×, UDG, One Tube) | BioReagent, DNase, RNase free, Suitable for molecular biology, PCR Reagent, for DNA and RNA applications, 2× | Single-tube system contains UDG enzyme, reducing carryover contamination risk from amplicons; suitable for qPCR workflows following reverse transcription of Nipah virus RNA, facilitating quality control management. |
P1491688 | UltraBio™ 2× Taq Platinum Universal SYBR Green Premix (ROX Separated) | BioReagent, DNase, RNase free, Suitable for molecular biology, PCR Reagent, for DNA and RNA applications | SYBR Green system suitable for real-time PCR/RT-PCR detection; ROX dye used for signal normalization/correction, helps improve result consistency and comparability. |
M751562 | UltraBio™ Multiplex Amplification Mix | BioReagent, DNase, RNase free, PCR Reagent, for DNA and RNA applications, Suitable for molecular biology | Supports multiplex amplification; allows incorporation of Nipah virus and other pathogen nucleic acids into the same detection panel, suitable for differential diagnosis scenarios. |
H1492589 | HiFi Hotstart PCR Mix | BioReagent, DNase, RNase free, PCR Reagent, UltraBio™, Suitable for molecular biology, for DNA and RNA applications | High-fidelity + hot-start design reduces non-specific amplification; suitable for Nipah virus-related nucleic acid detection and verification workflows requiring high amplification accuracy. |
U1492592 | UltraBio™ Robust Anstart-D PCR Mix (UDG) | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | UDG contamination prevention coupled with robust amplification capability; suitable for nucleic acid amplification workflows from complex samples like blood and body fluids, resistant to inhibitors and matrix interference. |
U1492577 | UltraBio™ StableMax RT-qPCR Master Mix (Dye, UDG, One Tube) | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | Single-tube one-step RT-qPCR system, contains dye and UDG; suitable for rapid detection and batch screening of Nipah virus RNA. |
U1492576 | UltraBio™ Hotstart HiTaq HS III One-step RT-PCR Mix | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | One-step reverse transcription-amplification integration, hot-start helps reduce background; suitable for rapid amplification detection of Nipah virus RNA. |
U1492590 | UltraBio™ Hotstart HiTaq& Super M-MuLV One Step RT-qPCR Kit (UDG) | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | Contains M-MuLV reverse transcriptase and UDG; high reverse transcription efficiency and strong contamination resistance, suitable for one-step RT-qPCR quantitative detection of Nipah virus RNA. |
U1492582 | UltraBio™ StableMax RT-qPCR Master Mix (UDG, One Tube) | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | Single-tube system with good stability and contains UDG for contamination prevention; suitable for batch sample processing in Nipah virus nucleic acid detection, aiding result consistency and traceability. |
U1492587 | UltraBio™ StableLink RT-qPCR Probe Kit (UDG) | BioReagent, DNase, RNase free, PCR Reagent, Suitable for molecular biology, for DNA and RNA applications | Probe-based method offers higher specificity, UDG reduces contamination risk; suitable for confirmatory detection of Nipah virus nucleic acid, reducing cross-reaction risk and improving detection specificity. |
M1492602 | MeloScript Reverse Transcriptase | DNase, RNase free, Suitable for molecular biology, EnzymoPure™, for DNA and RNA applications, 200 U/μL | Efficiently catalyzes reverse transcription of Nipah virus RNA into cDNA; nuclease-free formulation helps protect template integrity, providing high-quality cDNA for subsequent PCR amplification. |
M1492596 | MeloScript Ⅱ Reverse Transcriptase | DNase, RNase free, Suitable for molecular biology, EnzymoPure™, for DNA and RNA applications, 200 U/μL | Stronger reverse transcriptase activity and resistant to low-temperature interference; suitable for RNA reverse transcription from low viral load samples, improving template conversion rate. |
T1506987 | Taq DNA Polymerase | -- | Catalyzes amplification of Nipah virus cDNA fragments, compatible with conventional PCR detection, suitable for basic screening and methodological verification. |
H1506981 | Hotstart HiTaq DNA Polymerase | -- | Hot-start feature prevents non-specific amplification at low temperatures; improves amplification specificity and sensitivity, suitable for low-abundance cDNA amplification detection. |
H1507245 | HiFi Seq Hotstart DNA Polymerase | -- | High-fidelity amplification reduces base misincorporation; suitable for Nipah virus nucleic acid sequence analysis and variant detection, supporting molecular epidemiological tracing. |
H1506904 | Hotstart HiTaq Ⅱ DNA Polymerase | -- | Second-generation hot-start design balances amplification efficiency and specificity; suitable for nucleic acid amplification from complex samples, resistant to matrix interference. |
P1492616 | PowerResist Taq DNA Polymerase | Suitable for molecular biology, EnzymoPure™, for DNA and RNA applications, 5 U/μL | Strong interference resistance, tolerates residual inhibitors; suitable for nucleic acid amplification from complex samples like respiratory specimens and blood. |
P1492611 | ProPrime Taq DNA Polymerase | Suitable for molecular biology, EnzymoPure™, for DNA and RNA applications, 5 U/μL | High primer-binding specificity, reduces non-specific bands; suitable for precise amplification and control verification of Nipah virus nucleic acid. |
A1492607 | AK Taq DNA Polymerase V2 | Suitable for molecular biology, EnzymoPure™, for DNA and RNA applications, 5 U/μL | Fast amplification speed and good stability; suitable for rapid amplification detection of batch samples, supporting emergency testing needs. |
T1492985 | T4 DNA Polymerase | -- | Can be used for nucleic acid fragment end modification and end-filling; suitable for molecular experimental scenarios such as viral nucleic acid cloning and sequence verification. |
E1507342 | Epitech HS Taq DNA Polymerase | -- | Hot-start high-specificity amplification; suitable for low-concentration nucleic acid detection, reducing false-negative risk. |
E1507353 | Epitech Taq DNA Polymerase | -- | Conventional amplification enzyme, cost-effective; suitable for basic experiments and methodological verification control experiments. |
IV. Protein-Based Detection of Nipah Virus
4.1 ELISA: Laboratory Detection Centered on the Immunoenzymatic Method
(1) Basic Principle: Utilizes the specific binding of antigen and antibody, amplifying the binding event into a measurable signal through an enzyme-labeled detection system to achieve qualitative or semi-quantitative detection of NiV antigens or specific antibodies (commonly IgM/IgG).
(2) Common Detection Types and Significance:
① Antibody ELISA (IgM/IgG): IgM is primarily used to suggest possible recent infection, while IgG more often reflects evidence of past exposure or an established immune response.
② Antigen ELISA: Targets the direct detection of viral proteins, with positivity more common in samples with higher viral load or from earlier disease stages.
(3) Applicable Scenarios:
① Supplementary confirmation and disease staging following nucleic acid testing (especially after the nucleic acid detection window period);
② Retrospective investigation, exposure assessment, and population serological surveillance;
③ Jointly constructing an evidence chain with clinical presentation, exposure history, and nucleic acid test results.
(4) Interpretation and Quality Control Points:
① Time Window Constraint: The appearance and peak of antibodies show individual variation; an early negative result cannot rule out infection, and a single positive antibody result should not be directly equated with "currently infectious."
② Specificity Constraint: In low-prevalence areas or small-sample surveys, the positive predictive value is more susceptible to the baseline prevalence level. Interpretation should be cautious, combining repeat testing, dynamic changes in paired sera, and methodological specificity indicators.
③ Quality Control: Requires setting appropriate negative/positive controls and an interpretation threshold strategy, paying attention to cross-reactions and non-specific signals. Key conclusions are recommended to be validated for consistency with nucleic acid test results and epidemiological information.
4.2 Other Protein-Based Detection Methods:
Rapid antigen tests (e.g., immunochromatographic assays) can be used for rapid preliminary information feedback within a workflow, but their overall sensitivity and negative predictive value are generally inferior to standardized nucleic acid testing. Positive results require confirmation in conjunction with quality control checks and review within a multi-evidence chain.
4.3 Summary of Advantages and Limitations of Protein-Based Detection
(1) Advantages:
ELISA holds greater value in obtaining retrospective evidence, conducting population serosurveys, and disease stage stratification.
(2) Limitations:
Antigen detection sensitivity is significantly affected by viral load; antibody detection is limited by the delay in immune response establishment. Overall, protein-based results should be interpreted within a combined clinical-exposure history-nucleic acid framework, avoiding absolutization based on a single result.
4.4 Aladdin Related Products
Product Category | Product Code | Name | Specification or Purity | Purpose / Application |
Chromogenic Substrate | ABTS Solution | for ELISA, solution (ready-to-use) | HRP chromogenic substrate system, suitable for ELISA endpoint reading, used for colorimetric detection. | |
Buffer | ELISA Blocking Buffer | BioReagent, for protein analysis, for ELISA, sterile-filtered, ready-to-use, 1% | Blocks nonspecific binding sites on microplate wells, reduces background, improves signal-to-noise ratio. | |
Buffer | ELISA Wash Buffer (10x) | BioReagent, for protein analysis, for ELISA, sterile-filtered, 10x | Washes away unbound antibodies/antigens, reduces nonspecific signals, improves assay repeatability. | |
Stop Solution | ELISA Stop Solution (Ready-to-use) | BioReagent, for protein analysis, for ELISA, 0.5M | Stops the chromogenic reaction and stabilizes color, facilitating absorbance reading at wavelengths such as 450 nm. | |
Blocking Solution | UltraBio™ Blocking Buffer (PBS) | BioReagent, for western blot, for ELISA, ready-to-use, 1× | General-purpose blocking solution, used for ELISA plate blocking and Western blot (WB) blocking, reduces nonspecific background. | |
Blocking Solution | UltraBio™ Blocking Buffer (PBSTx) | BioReagent, for western blot, for ELISA, ready-to-use, 1× | Contains surfactant system, improves washing efficiency and background control, suitable for ELISA and WB. | |
Blocking Solution | UltraBio™ Blocking Buffer (TBS) | BioReagent, for western blot, for ELISA, ready-to-use, 1× | TBS-based blocking system, suitable for ELISA/WB systems incompatible with PBS-based buffers. | |
Blocking Solution | UltraBio™ Blocking Buffer (TBSTw) | BioReagent, for western blot, for ELISA, ready-to-use, 1× | TBST-based blocking system, balances blocking efficiency and background control, suitable for ELISA and WB. | |
Blocking Solution | UltraBio™ Blocking Buffer (TBSTx) | BioReagent, for western blot, for ELISA, ready-to-use, 1× | Enhanced background control TBST-based blocking system, suitable for high-background samples or high-sensitivity detection. | |
Blocking Solution | UltraBio™ Blocking Buffer(PBSTw) | BioReagent, for western blot, for ELISA, 1× | PBST-based blocking system, suitable for nonspecific adsorption inhibition in ELISA and WB. | |
Stop Solution | Alkaline Phosphatase Stop Solution | for ELISA | Stop solution for AP-based ELISA chromogenic reactions, stabilizes signal, suitable for terminating alkaline phosphatase substrate reactions. | |
Avidin-Related | Recombinant Monomeric Streptavidin (r-mSA) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), ≥8 U/mg | Binding component for biotin-streptavidin amplification systems, suitable for ELISA signal amplification and detection using biotinylated antibodies/antigens. | |
Avidin-Related | Recombinant Core Streptavidin (r-cSA) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), ≥15 U/mg | High-affinity binding component for biotin-based systems, used for ELISA detection and signal amplification, also applicable in IHC systems. | |
Avidin-Related | Recombinant Core Streptavidin 2 (r-cSA2) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), ≥16 U/mg | Binding component for biotin-based systems, used for ELISA detection and amplification, suitable for systems requiring higher binding efficiency. | |
Avidin-Related | Recombinant Core Streptavidin 4 (r-cSA4) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), 16 U/mg | Binding component for biotin-based systems, used for ELISA detection and signal amplification, compatible with various labeling strategies. | |
Avidin-Related | Recombinant Sticky Streptavidin (r-ScSA) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), ≥14 U/mg | Binding component for biotin-based systems, used for ELISA detection and signal amplification, suitable for systems requiring stronger binding characteristics. | |
Avidin-Related | Recombinant Long-Arm Sulfhydryl Group Core Streptavidin (r-las-cSA) | BioReagent, for protein analysis, for ELISA, Suitable for Immunohistochemistry(IHC), ≥95%(SDS-PAGE), ≥16 U/mg | Binding component for biotin-based systems, used for ELISA detection and amplification, suitable for binding biotinylated molecules with strong steric hindrance or conformational sensitivity. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG Antibody | See COA | Secondary antibody system, for general recognition and signal development related to human IgG in ELISA detection. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Mouse IgG (Biotin) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | Biotinylated secondary antibody, for ELISA detection using biotin-streptavidin amplification systems. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Mouse IgG (HRP) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | HRP-conjugated secondary antibody, for direct chromogenic readout in ELISA detection. | |
Secondary Antibody & Detection Reagent | Goat Anti-Chicken IgY H&L Antibody | Carrier Free, ExactAb™, Azide Free, Validated, See COA | Anti-chicken IgY secondary antibody, for detection and signal amplification in ELISA systems using chicken-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Goat Anti-Chicken IgY H&L (HRP) | ExactAb™, High Performance, Validated, 1 mg/mL | HRP-conjugated anti-chicken IgY secondary antibody, for chromogenic detection in ELISA. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG H&L (HRP) | ExactAb™, High Performance, Validated, 1 mg/mL | HRP-conjugated anti-human IgG secondary antibody, for chromogenic detection in ELISA. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG (Biotin) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | Biotinylated anti-human IgG secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG (HRP) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | HRP-conjugated anti-human IgG secondary antibody, for chromogenic detection in ELISA. | |
Secondary Antibody & Detection Reagent | Goat Anti-Rabbit IgG H&L Antibody | ExactAb™, Validated, Carrier Free, Azide Free, High performance, 6.0 mg/mL | Anti-rabbit IgG secondary antibody, for detection and signal amplification in ELISA systems using rabbit-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Goat Anti-Rabbit IgG H&L (Biotin) | ExactAb™, High Performance, Validated, 1 mg/mL | Biotinylated anti-rabbit IgG secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Goat IgG H&L (HRP) | ExactAb™, High Performance, Validated, 1.0 mg/mL | HRP-conjugated anti-goat IgG secondary antibody, for detection in ELISA systems using goat-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Mouse IgG H&L (HRP) | ExactAb™, High Performance, Validated, 1.0 mg/mL | HRP-conjugated anti-mouse IgG secondary antibody, for detection in ELISA systems using mouse-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG Fc (Alkaline Phosphatase) | ExactAb™, Validated, See COA | AP-conjugated secondary antibody, for chromogenic detection in ELISA using AP substrate systems, specifically recognizes human IgG Fc region. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG Fc (Biotin) | ExactAb™, Validated, 1.0 mg/mL | Biotinylated Fc-specific secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Donkey Anti-Rabbit IgG H&L (Biotin) | ExactAb™, High Performance, Validated, Azide Free, 2 mg/mL | Donkey-source biotinylated anti-rabbit IgG secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Goat IgG H&L (HRP) | ExactAb™, Validated, Azide Free, 1.0 mg/mL | HRP-conjugated anti-goat IgG secondary antibody, for detection in ELISA systems using goat-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Rabbit Anti-Goat IgG H&L (Biotin) | ExactAb™, Validated, Azide Free, High Performance, 1.0 mg/mL | Biotinylated anti-goat IgG secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Goat Anti-Chicken IgY H&L (HRP) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | HRP-conjugated anti-chicken IgY secondary antibody, for chromogenic detection in ELISA. | |
Secondary Antibody & Detection Reagent | Goat Anti-Chicken IgY H&L Antibody | ExactAb™, Validated, Carrier Free, Azide Free, High performance, 6.0 mg/mL | Anti-chicken IgY secondary antibody, for detection and signal amplification in ELISA systems using chicken-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Goat Anti-Mouse IgG H&L (HRP) | ExactAb™, High Performance, Validated, 1 mg/mL | HRP-conjugated anti-mouse IgG secondary antibody, for detection in ELISA systems using mouse-derived primary antibodies. | |
Secondary Antibody & Detection Reagent | Goat Anti-Rabbit IgG H&L (Alkaline Phosphatase) | ExactAb™, Validated, See COA | AP-conjugated anti-rabbit IgG secondary antibody, for chromogenic detection in ELISA using AP substrate systems. | |
Secondary Antibody & Detection Reagent | Goat Anti-Human IgG (Alkaline Phosphatase) | ExactAb™, Validated, See COA | AP-conjugated anti-human IgG secondary antibody, for chromogenic detection in ELISA using AP substrate systems. | |
Secondary Antibody & Detection Reagent | Goat Anti-Rabbit IgG H&L (Biotin) (Ready to use) | ExactAb™, Validated, See COA | Ready-to-use biotinylated anti-rabbit IgG secondary antibody, for streptavidin-based amplification systems in ELISA detection. | |
Secondary Antibody & Detection Reagent | Goat Anti-Chicken IgY H&L (Biotin) | ExactAb™, High Performance, Validated, Azide Free, 1.0 mg/mL | Biotinylated anti-chicken IgY secondary antibody, for streptavidin-based amplification systems in ELISA detection. |
V. Integrated Testing Pathway and Results Interpretation Framework
5.1 Selection of Testing Methods Based on Disease Stage
(1) Acute Early/Acute Phase: Nucleic acid detection (real-time RT-PCR) is the preferred confirmatory method. Antigen detection may be used only for rapid triage within the workflow or as supplementary information and does not replace nucleic acid testing for confirmation.
(2) Later/Convalescent Phase and Retrospective Investigation: Antibody detection (e.g., ELISA, etc.) is primary. Priority should be given to collecting paired sera, using dynamic changes in antibody levels (seroconversion or significant rise in titer) to strengthen the serological evidence.
5.2 Key Result Interpretation Rules
(1) Negative Does Not Equal Exclusion: Requires comprehensive judgment based on the clinical time window, sample type, and sampling quality; re-sampling and re-testing may be necessary, optimizing the sampling site and time point.
(2) Nucleic Acid Positive: Indicates direct etiological evidence of active infection. Transmission risk assessment and infection control decisions require integrated evaluation based on disease stage and contact scenario.
(3) Antibody Positive: Indicates evidence of an immune response. A single positive sample should not be directly equated with current infection or infectiousness. Dynamic serological evidence from paired acute and convalescent sera is more conclusive.
5.3 Comparison of Testing Methods
Testing Category/Method | Key Target | More Suitable Disease Stage | Core Purpose | Key Interpretation Points |
Real-time Fluorescent RT-PCR (Nucleic Acid) | Viral RNA | Acute Early/Acute Phase | Early Screening and Confirmation | A negative result does not have exclusion power (affected by time window and sample quality); Detection of nucleic acid does not directly equate to transmissibility of live virus. |
ddPCR/Isothermal Amplification, etc. (Nucleic Acid Supplement) | Viral RNA | Supplementary in Specific Scenarios | Improve Detection Capability or Increase Field Accessibility | Requires completion of methodological validation and incorporation into quality control; Results should be interpreted after consistency calibration with standard RT-PCR. |
Antigen Detection (Protein) | Viral Protein | Primarily Acute Phase (High Viral Load Stage) | Rapid Triage / Supplementary Information | Sensitivity is significantly affected by viral load; Negative predictive value is limited; Positive results are recommended for review and consistency verification with nucleic acid tests and clinical-epidemiological information. |
Antibody ELISA, etc. (Serology) | Specific Antibodies (e.g., IgM, IgG) | Later/Convalescent Phase and Retrospective Investigation | Supplementary Confirmation, Retrospective Assessment, and Population Surveillance | A serological window period exists; A positive antibody result does not equate to current infection or infectiousness; Dynamic evidence from paired sera is more powerful. |
5.4 Biosafety
(1) Compliance First: The handling and testing of NiV-related samples must comply with applicable regulations, requirements from competent authorities, and the institution's approved Standard Operating Procedures (SOPs), and should be conducted only after completing a risk assessment and personnel authorization.
(2) Risk-Based Approach: Prior to effective inactivation or other risk control measures, samples must be managed as high-risk material. Relevant procedures should employ engineering controls, administrative controls, and personal protective equipment commensurate with the risk level, avoiding the compromise of key safety requirements for the sake of efficiency.
(3) Closed-Loop Management: Maintain traceability throughout the entire process. Any anomalies, such as suspected contamination, discrepant results, or potential exposure incidents, must trigger immediate review, reporting, and the implementation of corrective and preventive actions (CAPA) according to institutional protocols.
The core of the NiV diagnostic framework lies in utilizing nucleic acid detection to provide high-evidence-level conclusions for current infection during the acute phase, while antigen and serological antibody assays fill evidence gaps at different time points. Binding diagnostic conclusions to the specific detection subject, disease time window, sample type, and quality control context is paramount for enhancing interpretability, comparability, and actionability of results.
For more related articles, please see below:
[1] Application of mRNA reverse transcription amplification of cDNA (RT-PCR)
[2] RT-PCR
[3] ELISA Methods
[4] For enzyme immunoassay(ELISA)
Aladdin: https://www.aladdinsci.com/